Cargando…

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells

Chronic myelocytic leukemia (CML) is a frequently encountered type of leukemia in China. Hypoxia-inducible factor 1 (HIF-1) serves as one of the most important factors of oxygen balance transcription. The activation of this gene mostly marks a poor outlook for cancer patients. To clarify the therape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuexian, Chen, Heng, Shen, Yunfeng, Zhou, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071866/ https://www.ncbi.nlm.nih.gov/pubmed/35528614 http://dx.doi.org/10.1155/2022/6324326

Ejemplares similares

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole
por: Yuan, Yuting, et al.
Publicado: (2023)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia
por: Yu, Guopan, et al.
Publicado: (2017)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
por: García-Gutiérrez, Valentín, et al.
Publicado: (2020)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Priapism due to chronic myelocytic leukemia
por: Syarif, et al.
Publicado: (2021)

Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
por: Saladi, Venkata Narasayya, et al.
Publicado: (2022)

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
por: Gu, Yue, et al.
Publicado: (2023)

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor
por: Muñoz, Juan D, et al.
Publicado: (2019)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
por: Xiao, Xinhua, et al.
Publicado: (2020)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

EXTENSIVE CUTANEOUS MANIFESTATIONS: PRESENTING FEATURE OF CHRONIC MYELOCYTIC LEUKEMIA IN SECOND BLAST CRISIS
por: Singhal, Manish, et al.
Publicado: (2010)

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
por: Borriello, Adriana, et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
por: Rodríguez-Agustín, Andrea, et al.
Publicado: (2023)

Influence of 2‐Methoxyestradiol and Sex on Hypoxia‐Induced Pulmonary Hypertension and Hypoxia‐Inducible Factor‐1‐α
por: Docherty, Craig K., et al.
Publicado: (2019)

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
por: Glodkowska-Mrowka, E, et al.
Publicado: (2016)

Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
por: Shacham Abulafia, Adi, et al.
Publicado: (2020)

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
por: Batth, Izhar Singh, et al.
Publicado: (2021)

Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome
por: Piekarska, Agnieszka, et al.
Publicado: (2015)

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
por: Simões, Belinda Pinto, et al.
Publicado: (2011)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience
por: Ribeiro, Beatriz Felicio, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-primed Bone Marrow: An Excellent Stem-cell Source for Transplantation in Acute Myelocytic Leukemia and Chronic Myelocytic Leukemia
por: Li, Yuhang, et al.
Publicado: (2015)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_g6mm781bq0bj8pl5lhck3flmil